We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Vitamin D Supplementation on Hemoglobin A1c

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01354262
Recruitment Status : Completed
First Posted : May 16, 2011
Last Update Posted : April 23, 2015
Information provided by (Responsible Party):
Prabhat Pokhrel, Genesys Regional Medical Center

Brief Summary:
This is a prospective, randomized, non-blinded interventional study that will investigate the effect of a vitamin D supplement on HbA1c in patients with uncontrolled type 2 diabetes mellitus (DM) and vitamin D deficiency. The goal is to investigate whether correcting vitamin D deficiency will alter the HbA1c level in patients with type 2 DM and lower than normal vitamin D level. My hypothesis is that correcting vitamin D deficiency decreases HbA1c levels in patients with type 2 DM and vitamin D deficiency.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Vitamin D Deficiency Dietary Supplement: Vitamin D Phase 2

Detailed Description:

The total number of study subjects expected to be enrolled in this study is about 150. Study subjects included in this study will be men and women between 34-69 years of age who have been diagnosed with type 2 DM based on at least one of the American Diabetic Association criteria. These criteria are 1) fasting blood glucose higher than 125 mg/dL once with symptoms of diabetes (increased urination, increased appetite, increased thirst) or two times without symptoms; 2) random blood glucose more than 200 mg/dL once with symptoms or two times without symptoms of diabetes; 3) two hour glucose tolerance test more than 200 mg/dL once with symptoms or two times without symptoms; or 4) a random glycosylated hemoglobin more than 6.5 % two times. The age group for this research was selected based on the review of the literature on diabetes and vitamin D. Patients with known primary hyperparathyroidism, sarcoidosis, tuberculosis, cancer, potential terminal illness, history of serum creatinine more than 2.0 mg/dL, vitamin D supplement more than 200 IU/day, inflammatory bowel disease and history of hypercalcemia and kidney stones will be excluded from this study. For this project, vitamin D deficiency is defined as serum vitamin D level lower than 30 ng/mL and uncontrolled diabetes is defined as HbA1C level above 7.0. Although there is more than one recommended normal level of vit. D in the blood, most experts agree that the optimum serum level of vitamin D should be above 30 ng/mL. All subjects will be receiving standard of care for DM offered to them by his or her physician.

The investigators will investigate if different but fixed doses of vitamin D (600 IU a day vs 50,000 IU once every other week) when given to patients with type 2 DM and vitamin D deficiency have different effects on HbA1c level at the end of 24 weeks. A baseline blood draw, and fasting blood draws will be taken at 12 and 24 weeks for blood sugar levels, Vit D levels, and HgbA1c. Subjects with vitamin D deficiency will be randomly assigned to either group 1 or 2 and will be supplemented with either 600 IU of vitamin D/day (Group 1) or 50,000 IU of vitamin D every 2 weeks for 24 weeks (Groups 2). Patients who are not vitamin D deficient will be followed as the control group (Group 3) and will not be given any vitamin D supplement.Research subjects will be advised not to take any vitamin D or multivitamin while participating in this study. Subjects will be given 100 tablets of 600 IU of vitamin D in a bottle if they belong to Group 1. If they have been advised to take vitamin D 50,000 IU once every 14 days (Group 2), they will be given altogether 13 tablets of 50,000 of vitamin D each in a separate brown envelope with date written on the envelop and subjects will be asked to take vitamin D only on the date written on the envelop.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Does Vitamin D Supplement Alter Serum Level of Glycosylated Hemoglobin in Adult Patients Between 34-74 Years With Type 2 Diabetes Mellitus and Vitamin D Deficiency?
Study Start Date : March 2011
Primary Completion Date : January 2012
Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Lower dose vitamin D
Fixed daily doses of 600 IU vitamin D oral supplementation.
Dietary Supplement: Vitamin D
600 IU daily oral supplementation
Experimental: Higher dose vitamin D
50,000 IU supplementation bi-monthly.
Dietary Supplement: Vitamin D
50,000 IU supplementation bi-monthly
No Intervention: Control Group
Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.

Primary Outcome Measures :
  1. Change in serum levels of Hemoglobin A1c. [ Time Frame: Change from baseline assessed at 12 wk and 24 wk. ]
    Serum levels of hemoglobin A1c will be tested in the laboratory from blood draws conducted at baseline and at 12 and 24 weeks from a fasting blood sample.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   34 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes mellitus
  • Hgb A1c greater then 7.0
  • Adults aged 34 to 69 years.

Exclusion Criteria:

  • known primary hyperparathyroidism, sarcoidosis, tuberculosis, cancer, potential terminal illness,
  • history of serum creatinine more than 2.0 mg/dL,
  • vitamin D supplement more than 200 IU/day
  • history of inflammatory bowel disease, hypercalcemia or kidney stones

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01354262

United States, Michigan
Genesys East Flint Campus Clinic
Flint, Michigan, United States, 48503
Sponsors and Collaborators
Genesys Regional Medical Center
Principal Investigator: Prabhat K Pokhrel, MD Genesys Regional Medical Center
Study Director: Kimberly R Barber, PhD Genesys Regional Medical Center

Responsible Party: Prabhat Pokhrel, Physician, Genesys Regional Medical Center
ClinicalTrials.gov Identifier: NCT01354262     History of Changes
Other Study ID Numbers: GRMC 10 0023
First Posted: May 16, 2011    Key Record Dates
Last Update Posted: April 23, 2015
Last Verified: April 2015

Keywords provided by Prabhat Pokhrel, Genesys Regional Medical Center:
Vitamin D deficiency
Hemoglobin A1c

Additional relevant MeSH terms:
Diabetes Mellitus
Vitamin D Deficiency
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents